In 2018, two critical events brought this issue front and center in every pet-owning household in the country. First, in September 2018, the U.S. Drug Enforcement Agency (DEA) reclassified drugs that contained certain cannabis components. As a result, FDA-approved drugs that contain CBD (cannabidiol) derived from cannabis and no more than 0.1% tetrahydrocannabinols (THC) are now in Schedule V, rather than Schedule I (drugs that have no currently accepted medical use and a high potential for abuse). Other Schedule V drugs include cough preparations with less than 200 mg of codeine per 100 ml (Robitussin AC), Lomotil, Motofen, Lyrica, and Parepectolin. Marijuana, as distinguished from cannabis, remained on Schedule I along with heroin, LSD, ecstasy, peyote, etc.
